Stay updated with breaking news from Jonathan Strosberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that the Company will be
The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours - News - PharmaTimes
email article The multitargeted tyrosine kinase inhibitor (TKI) lenvatinib induced a strong tumor response in patients with previously treated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to results from a phase II trial in Europe. In this multicenter, open-label study involving 111 patients, treatment with lenvatinib (Lenvima) led to an overall response rate (ORR) of 29.9%, with a particularly high ORR -- 44.2% -- in patients with pancreatic NETs, reported Jaume Capdevila, MD, PhD, of Vall Hebron University Hospital in Barcelona, and colleagues . "Thi...